This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Korbonits, M. Articles by Trainer, P. J. Search for Related Content PubMed PubMed Citation Articles by Korbonits, M. Articles by Trainer, P. J.

The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin

Departments of Endocrinology and Chemical Endocrinology (L.A.P.), St. Bartholomew’s Hospital, London, United Kingdom EC1A 7BE

Address all correspondence and requests for reprints to: Dr. Márta Korbonits, Department of Endocrinology, St. Bartholomew’s Hospital, West Smithfield, London, United Kingdom EC1A 7BE. E-mail: m.korbonits{at}mds.qmw.ac.uk

GH secretagogues (GHSs) act via specific receptors in the hypothalamus and the pituitary gland to release GH. GHSs also stimulate the hypothalamo-pituitary-adrenal (HPA) axis via central mechanisms probably involving CRH or arginine vasopressin (AVP). We studied the effects of hexarelin, CRH, and desmopressin, an AVP analog, on the stimulation of the HPA axis in 15 healthy young male volunteers. Circulating ACTH, cortisol, GH and PRL concentrations were measured for 2 h after the injection of hexarelin, CRH, or desmopressin alone and the combination of hexarelin plus CRH or hexarelin plus desmopressin. Symptoms during the tests were assessed by visual analog scales. Hexarelin significantly increased ACTH and cortisol release (area under the curve, 3,444 ± 696 ng/L·125 min and 45,844 ± 2,925 nmol/L·125 min, respectively), and this effect was augmented by the addition of CRH in a dose that on its own produces maximal stimulation (6,580 ± 1,572 ng/mL·125 min and 63,170 ± 2,616 nmol/L·125 min; P = 0.01 and 0.001, respectively), but was not influenced by the addition of desmopressin (3,540 ± 852 ng/mL·125 min and 35,319 ± 3,252 nmol/L·125 min; not significant). CRH on its own caused similar or slightly higher ACTH and cortisol release than hexarelin alone. Desmopressin given alone elicited a rapid rise in circulating ACTH and cortisol, but its effects were less than those of any other treatment and were not augmented by hexarelin. Hexarelin also caused significant GH and PRL release, but these effects were not influenced by the coadministration of CRH or desmopressin. Visual analog scales showed an acute small increment in appetite with hexarelin. Our data suggest that the effect of GHSs on the HPA axis involve at least in part the stimulation of AVP release.

In summary, we have shown that in healthy male volunteers, the effect of hexarelin on the HPA axis does not involve CRH, but may occur through the stimulation of AVP release.

This article has been cited by other articles:

				A. Iranmanesh, P. C. Carpenter, K. Mielke, C. Y. Bowers, and J. D. Veldhuis Putative Somatostatin Suppression Potentiates Adrenocorticotropin Secretion Driven by Ghrelin and Human Corticotropin-Releasing Hormone J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3653 - 3659. [Abstract] [Full Text] [PDF]

				S. Siyambalapitiya, V. Ibbotson, A. Doane, E. Ghigo, M. J. Campbell, and R. J. Ross Combining Growth Hormone Releasing Hormone-Arginine and Synacthen Testing Diminishes the Cortisol Response J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 853 - 856. [Abstract] [Full Text] [PDF]

				T L Peeters Ghrelin: a new player in the control of gastrointestinal functions Gut, November 1, 2005; 54(11): 1638 - 1649. [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				J. C. Weikel, A. Wichniak, M. Ising, H. Brunner, E. Friess, K. Held, S. Mathias, D. A. Schmid, M. Uhr, and A. Steiger Ghrelin promotes slow-wave sleep in humans Am J Physiol Endocrinol Metab, February 1, 2003; 284(2): E407 - E415. [Abstract] [Full Text] [PDF]

				F. Obal Jr., J. Alt, P. Taishi, J. Gardi, and J. M. Krueger Sleep in mice with nonfunctional growth hormone-releasing hormone receptors Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2003; 284(1): R131 - R139. [Abstract] [Full Text] [PDF]

				S. Ishizaki, T. Murase, Y. Sugimura, S. Kakiya, H. Yokoi, K. Tachikawa, H. Arima, Y. Miura, and Y. Oiso Role of Ghrelin in the Regulation of Vasopressin Release in Conscious Rats Endocrinology, May 1, 2002; 143(5): 1589 - 1593. [Abstract] [Full Text] [PDF]

				S. Petersenn, A. C. Rasch, M. Penshorn, F. U. Beil, and H. M. Schulte Genomic Structure and Transcriptional Regulation of the Human Growth Hormone Secretagogue Receptor Endocrinology, June 1, 2001; 142(6): 2649 - 2659. [Abstract] [Full Text] [PDF]

				C. Y. Bowers Unnatural Growth Hormone-Releasing Peptide Begets Natural Ghrelin J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1464 - 1469. [Full Text]

				E. Arvat, M. Maccario, L. Di Vito, F. Broglio, A. Benso, C. Gottero, M. Papotti, G. Muccioli, C. Dieguez, F. F. Casanueva, et al. Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1169 - 1174. [Abstract] [Full Text]

				M. Moro, P. Putignano, M. Losa, C. Invitti, C. Maraschini, and F. Cavagnini The Desmopressin Test in the Differential Diagnosis between Cushing's Disease and Pseudo-Cushing States J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3569 - 3574. [Abstract] [Full Text]